KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-Current Assets (2018 - 2025)

Historic Non-Current Assets for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $3.6 million.

  • Esperion Therapeutics' Non-Current Assets fell 4578.44% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.1 million, marking a year-over-year decrease of 2633.4%. This contributed to the annual value of $5.8 million for FY2024, which is 2308.18% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Non-Current Assets is $3.6 million, which was down 4578.44% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Non-Current Assets registered a high of $54.6 million during Q3 2021, and its lowest value of $1.2 million during Q1 2023.
  • Moreover, its 5-year median value for Non-Current Assets was $5.8 million (2024), whereas its average is $17.2 million.
  • Per our database at Business Quant, Esperion Therapeutics' Non-Current Assets surged by 87412.52% in 2022 and then plummeted by 9766.69% in 2023.
  • Esperion Therapeutics' Non-Current Assets (Quarter) stood at $52.6 million in 2021, then tumbled by 97.61% to $1.3 million in 2022, then soared by 276.67% to $4.7 million in 2023, then increased by 23.08% to $5.8 million in 2024, then crashed by 38.93% to $3.6 million in 2025.
  • Its last three reported values are $3.6 million in Q3 2025, $4.5 million for Q2 2025, and $5.3 million during Q1 2025.